Huadao Bio-Medical Lands $14 Million In Series B Financing
Huadao Bio-Medical just received around 14 million dollars in Series B financing, this round of financing was led by NKY Pharma. The funds will be used for technological innovation and development of CAR-T drug, and the improvement of the company's drug production abilities.
Huadao Bio-Medical was founded in 2017, its products include leukemia, digestive tract tumors and other tumors treatment; it is also a pharmaceutical company with CAR-T industry technology. At present, Huadao Bio-Medical just finished CAR-T production equipment preparation and development of liquid nitrogen storage equipment.
This project will improve the technology independent of the Chinese companies in the field of CAR-T drug development, and can greatly improve cancer patients' lives around the world.
About NKY Pharma
Nanjing King-friend Biochemical Pharmaceutical is focused on research, production, and sales of raw material medicines of heparin sodium. It mainly produces a series of products including heparin sodium and low molecular heparin.